Dosage Charts Calculator Blends & Stacks Learn Blog Peptides
Open Calculator
Dosage Charts  ›  IGF-1 DES
Growth Factor

IGF-1 DES Guide & Dosage Chart

A truncated IGF-1 analog studied for localized anabolic effects.

Also known asDES(1-3) IGF-1
Routesubcutaneous
IGF-1 DES — Dosage chart
Every row cited
GoalDoseFrequencyDurationEvidenceSource
Cited dosing data is being compiled for this compound.
For research and educational use only. Not medical advice.

What is IGF-1 DES?

IGF-1 DES — short for DES(1-3) IGF-1 — is a naturally occurring, truncated version of Insulin-Like Growth Factor 1 (IGF-1). "Truncated" just means a few amino acids have been snipped off one end. Specifically, the first three amino acids at the N-terminus (the front of the protein chain) are missing. That small structural change turns out to make a surprisingly big functional difference. IGF-1 DES is found naturally in the brain and in the gut, and researchers have been studying it since the late 1980s as a research compound to understand local tissue growth and repair.

How IGF-1 DES Works

Think of regular IGF-1 like a taxi driver who has to check in with a dispatcher before picking up a passenger. The "dispatchers" are proteins in the bloodstream called IGF Binding Proteins (IGFBPs). These binding proteins grab onto regular IGF-1, slow it down, and control how much of it actually reaches its destination — the IGF-1 receptor on a cell.

IGF-1 DES is like a taxi that skips the dispatcher entirely. Because of its truncated structure, IGFBPs can't grip it as tightly. Research confirmed this directly: binding proteins that potently blocked regular IGF-1 activity had little to no effect on DES(1-3) IGF-1 activity, and the enhanced potency of DES was attributed precisely to this resistance to binding proteins.[2] That means more of it can reach cell receptors quickly and directly.

Once it arrives at the cell, IGF-1 DES activates the same receptor as regular IGF-1 — the Type 1 IGF receptor (IGF-1R). This receptor triggers internal signaling pathways, including one called the Akt pathway, which is involved in cell survival, growth, and metabolism. However, the story is more nuanced: one specific binding protein, IGFBP-3, appears able to dampen IGF-1R activation through a separate mechanism that doesn't even require it to physically grab the peptide first.[3]

Because IGF-1 DES doesn't bind well to carrier proteins, it also behaves differently in the bloodstream. Studies show it has a shorter half-life in blood and a slower rate of entry into the brain compared to regular IGF-1, which relies on binding proteins to hitch a ride across the blood-brain barrier.[5] This means IGF-1 DES may act more locally at the site of administration rather than traveling widely through the body — a key property researchers find interesting for studying localized tissue effects.

What the Research Shows

Diabetic Retina Studies

One of the more striking findings comes from research in diabetic rats. Diabetes causes early biochemical changes in the retina — the light-sensitive tissue at the back of the eye — long before visible damage appears. In one study, systemic treatment with DES(1-3) IGF-1 normalized abnormal accumulations of IGF receptors and a key signaling molecule (phospho-Akt) in the retinas of diabetic rats, even though blood sugar remained high. Preliminary findings also suggested reduced levels of VEGF, a protein tied to abnormal blood vessel growth in diabetic eye disease.[1]

Brain Injury Research

Researchers have also explored IGF-1 DES in models of brain injury. IGF-1 plays a well-documented role in the developing and injured brain, with its receptors and binding proteins highly expressed in brain tissue.[6] However, when scientists compared IGF-1 and DES(1-3) IGF-1 directly after hypoxic-ischemic brain injury in adult rats, regular IGF-1 (injected into the brain ventricle) significantly reduced neuronal loss across multiple brain regions, while DES(1-3) IGF-1 at standard doses did not show the same protection.[4] A trend toward benefit appeared only at a much higher dose.[4] Separately, in an olfactory bulb brain culture model, DES(1-3) IGF-1 was similarly ineffective, suggesting that local IGFBPs may actually help target IGF-1 to the right receptors in certain brain contexts.[6] This is a good reminder that "bypasses binding proteins" isn't always an advantage — context matters enormously in research.

Blood-Brain Barrier Pharmacokinetics

A dedicated pharmacokinetic study found that DES(1-3) IGF-1 had a shorter half-life in blood and a slower brain influx rate than regular IGF-1. Unlike regular IGF-1, it showed no change in pharmacokinetics when extra unlabeled peptide was added, confirming it does not use the same binding-protein-assisted transport system to cross the blood-brain barrier.[5]

What IGF-1 DES Is Being Studied For

  • Localized muscle and tissue anabolic signaling (preclinical models)
  • Early retinal changes in diabetes models[1]
  • Neuroprotection and brain injury recovery (comparative studies)[4][6]
  • Understanding the role of IGF binding proteins in growth factor biology[2][3]
  • Blood-brain barrier transport mechanisms[5]

All of this work is preclinical or mechanistic research. IGF-1 DES is a research compound — it is not approved for human therapeutic use.

How IGF-1 DES Is Dosed in Research

Dosing in published studies has varied widely depending on the research model, route of administration, and tissue target being studied — for example, the brain injury study used intracerebroventricular doses ranging from 2 µg to 150 µg in rats.[4] Because dosing is highly context-dependent and this is a research-use-only compound, we strongly recommend consulting the dosage chart on this page for a structured reference overview, and using the calculator to work through precise unit conversions for your research protocol. Never extrapolate animal study doses directly to any other context.

Mixing and Storing IGF-1 DES

IGF-1 DES typically arrives as a lyophilized (freeze-dried) white powder sealed under vacuum or inert gas. To reconstitute it, researchers generally add bacteriostatic water or sterile water slowly down the side of the vial — not directly onto the powder — and gently swirl (never shake) until fully dissolved. Shaking can damage the peptide's delicate structure. Because IGF-1 DES is a protein, it's sensitive to heat, repeated temperature changes, and light. Once reconstituted, store it refrigerated (around 2–8 °C) and use it within a few weeks for best stability. Unopened lyophilized vials can typically be stored frozen for longer periods. Always check the specific product documentation for storage guidance, label each vial with the date of reconstitution, and use sterile technique throughout.

Sources

  1. Des(1-3)IGF-1 treatment normalizes type 1 IGF receptor and phospho-Akt (Thr 308) immunoreactivity in predegenerative retina of diabetic rats. — International journal of experimental diabesity research, 2003. PMID 12745670.
  2. Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1. — The Biochemical journal, 1989. PMID 2539101.
  3. Insulin-like growth factor (IGF) binding protein-3 inhibits type 1 IGF receptor activation independently of its IGF binding affinity. — Endocrinology, 2001. PMID 11145572.
  4. The effects of insulin-like growth factor (IGF)-1, IGF-2, and des-IGF-1 on neuronal loss after hypoxic-ischemic brain injury in adult rats: evidence for a role for IGF binding proteins. — Endocrinology, 1996. PMID 8603600.
  5. Interactions of IGF-1 with the blood-brain barrier in vivo and in situ. — Neuroendocrinology, 2000. PMID 11025411.
  6. The role of the insulin-like growth factor system in the developing brain. — Hormone research, 1998. PMID 9554468.

IGF-1 DES FAQ

What is IGF-1 DES?
IGF-1 DES (also called DES(1-3) IGF-1) is a naturally occurring, shortened version of Insulin-Like Growth Factor 1. Its first three amino acids are missing, which reduces how tightly it binds to IGF binding proteins in the body.[2] This makes it a useful research tool for studying localized growth factor signaling. It is a research compound, not approved for human therapeutic use.
How does IGF-1 DES work?
IGF-1 DES activates the same cell receptor as regular IGF-1 (the Type 1 IGF receptor), triggering growth and survival signals inside cells. Its key difference is that IGF binding proteins — which normally intercept regular IGF-1 — have little effect on it, so it can reach receptors more directly.[2] However, IGFBP-3 can still dampen IGF-1 receptor activation through a separate mechanism.[3]
What is IGF-1 DES used for in research?
Researchers have studied IGF-1 DES in models of diabetic retinal changes,[1] brain injury recovery,[4] and blood-brain barrier pharmacokinetics.[5] It is also used as a scientific tool to understand the role of IGF binding proteins in regulating growth factor activity.[2][3] All known research is preclinical — no approved human therapeutic applications exist.
How is IGF-1 DES dosed in research studies?
Doses vary greatly by study model and route. For example, one brain injury study in rats used intracerebroventricular doses from 2 µg to 150 µg, with effects only trending at the highest dose.[4] There is no standardized human dose, as this is a research-only compound. Refer to the dosage chart and calculator on this page for structured reference information.
How do you reconstitute IGF-1 DES?
Add bacteriostatic or sterile water slowly down the inside wall of the vial — never directly onto the powder. Gently swirl until dissolved; do not shake, as agitation can degrade the peptide. Once reconstituted, store refrigerated at 2–8 °C and use within a few weeks. Keep away from light and avoid repeated freeze-thaw cycles. Always follow sterile technique and the specific product documentation.
Is IGF-1 DES safe?
IGF-1 DES is a research compound only and has not been evaluated for safety or efficacy in humans through clinical trials. Animal studies have examined it in specific models,[1][4] but results vary by context. This page is for educational and research reference purposes only and does not constitute medical advice. Consult qualified professionals before handling any research peptide.